CClinicalTrials.gg
RecruitingNCT06824402Updated May 1, 2026

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

An interventional study of Forceps Biopsy and Cryoprobe Biopsy in Lung Transplant Rejection, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate which biopsy collection method helps to better diagnose rejection and relevant pathologic findings in lung transplant recipients. The main questions it aims to answer are:

Does the 1.1 mm cryoprobe or the biopsy forceps provide better quality samples of lung tissue for detecting rejection in transplant recipients?

How much tissue is adequate for lung transplant 1.1 mm cryobiopsy samples as compared to biopsy forceps?

Which samples received by the pathologist did they find they were most confident to exclude rejection, based on their satisfaction with the samples?

Which collection method has the least amount of procedural time?

Researchers will compare lung tissue samples obtained using a 1.1mm cryoprobe and a biopsy forceps during the lung transplant.

Participants will:

Be randomly assigned to receive either the cryoprobe or biopsy forceps collection method at the time of biopsy.

Assessed for any adverse events following the biopsy for up to 30 days after transplant.

Read the detailed description

The purpose of this 1:1 randomized clinical trial is to compare the histological quality and diagnostic yield of tissue samples acquired using a 1.1 mm cryoprobe with those obtained with biopsy forceps in lung transplant recipients for graft surveillance.

02

Conditions studied

  • Lung Transplant Rejection

Keywords

  • Lung Transplant
  • Bronchoscopy
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female lung transplant recipients age >18 at the time of informed consent
  • Patients clinically meet indication for post-transplant lung biopsy or planned routine surveillance and have been scheduled for bronchoscopy with transbronchial biopsy.
  • Be willing and able to sign the informed consent.

Exclusion criteria

Exclusion Criteria

  • Patients with known bleeding diathesis
  • Platelet count \<50,000 per μL within 14 days of the biopsy procedure
  • Current use of systemic anticoagulation or antiplatelet therapy without the ability to hold therapy for the recommended amount of time prior to an invasive procedure (aspirin monotherapy is acceptable)
  • Inability or unwillingness to give informed consent or study procedures
  • Pregnant or nursing females, or females who intend to become pregnant
  • Females of child-bearing potential who decline a pregnancy test prior to enrollment
  • If an investigator does not feel that this study is in the subject's best interest or would be a good fit for the study.
  • International Normalized Ratio (INR) >1.5
  • Do Not Resuscitate (DNR) status
  • Do Not Intubate (DNI) status
  • Single lung transplant recipients
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cryoprobe Biopsy Method

    Cryoprobes which are flexible catheters that can be passed through the channel of a bronchoscope. Rapid cooling of tissue results from the Joule-Thomson effect which causes tissue to freeze and adhere to the probe. The biopsy is obtained by subsequently avulsing small fragments of tissue.

    Device: Cryoprobe Biopsy

  • Active comparator
    Forceps Biopsy Method

    Olympus disposable EndoJaw is used to obtain samples as per the standard of clinical care usually resulting in crush artifact.

    Device: Forceps Biopsy

Interventions

  • DeviceForceps Biopsy

    10-12 transbronchial lung biopsies will be obtained using standard of care biopsy forceps: Olympus disposable EndoJaw (FB-211), Olympus, USA

  • DeviceCryoprobe Biopsy

    3 transbronchial lung biopsies of two separate lobes will be obtained using a flexible cryoprobe: single-use, ø 1.1 mm (Erbe Elektromedizin GmbH, 20402-401) used with ERBECRYO 2 (Erbe Elektromedizin GmbH, 10402-000

06

What researchers measure

Primary outcomes

  1. Quality and diagnostic yield of tissue samples

    Histological accessibility grade is determined by the pathologist according to the Lung Allograft Standard Histological Analysis (LASHA) scale and the 2007 Revision of the 1996 working formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection, published by the ISHLT.

    Time frame: Baseline

Secondary outcomes

  1. Time duration

    Duration of each individual biopsy procedure from insertion of the bronchoscope after airway has been secured until bronchoscope is withdrawn. .

    Time frame: Baseline

  2. Tissue sample adequacy

    Number of biopsy samples that are adequate to determine rejection based on the presence of well expanded alveoli, as determined by the pathologist.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    • John Joerns · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824402
Lead sponsor
Mayo Clinic
Responsible party
John O. Joerns (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 13, 2025
Start date
Feb 17, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 1, 2026

Study contacts

John Joerns, MD
Contact
joerns.john@mayo.edu
507-284-6616
Jackie Reiter
Contact
reiter.jacqulyn@mayo.edu
507-538-2224
John Joerns
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion